Inclusion Criteria:  Subject is ≥ 18 years old Subject is willing and able to complete the follow-up requirements Subject has the mental capacity (i.e. does not require the use of a Legally Authorized Representative) to sign the study Informed Consent Form (ICF) Patient undergoing diagnostic or interventional endovascular procedure compatible with the use of FemoSeal™ VCS Puncture site located at the CFA (i.e. between the inferior epigastric artery and the bifurcation of the superficial and profunda femoral arteries) FemoSeal™ VCS deployed as per instruction for use by a trained operator on arteriotomy where sheaths or devices of ≤7F were used, following a femoral artery angiogram  Exclusion Criteria:  Any contraindication to the endovascular treatment and/or FemoSeal™ VCS use as per IFU Use of the FemoSeal™ VCS on puncture sites other than CFA Repuncture of the CFA within 90 days at the same access site  Enrollment of a patient with the contralateral CFA puncture, when a prior target limb access site has been selected for the study and a FemoSealTM deployment has been performed.  Additionally, patients will be examined intraoperatively and excluded from the study if any of the following were observed by the treating physician:  Lumen diameter of CFA < 5 mm Stenosis and/or significant plaque present in the vicinity of the CFA puncture site Arterial puncture is at, or distal to, the femoral artery bifurcation Anomalous branches or vessel abnormalities present in the vicinity of the CFA puncture site Use of > 7F primary introducer sheaths or devices Multiple femoral punctures Known or suspected posterior femoral wall puncture Any condition that would make use of the closure device inappropriate (as per investigators' discretion)